Amgen's Vectibix meets non-inferiority OS primary endpoint in Phase 3 study

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen's (AMGN) Vectibix meets its primary endpoint of non-inferiority (overall survival) to Erbitux (BMY, LLY, MKGAF.PK) in a Phase 3 trial in patients with wild-type KRAS metastatic colorectal cancer that has not responded to chemotherapy.

Median OS for Vectibix was 10.4 months compared to 10 months for Erbitux.

Median PFS for Vectibix was 4.1 months versus 4.4 months for Erbitux. (PR)